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ABSTRACT 
The potential application for stem cell therapy is vast and its development for 
use in ischaemic stroke is still at its infancy. Access to stem cells for research 
is contentious but various sources are obtainable from both animals and 
humans. Despite a limited understanding of their mechanisms of action, clinical 
trials assessing stem cells in human stroke have been performed. Trials are 
also underway evaluating haematopoietic precursors mobilised with 
granulocyte-colony stimulating factor, an approach offering an autologous 
means of administrating stem cells for therapeutic purposes. This review 
summarises current knowledge in regard of stem cells and their potential for 
helping improve recovery after stroke. 
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INTRODUCTION 
Stroke is the third leading cause of death worldwide and is devastating to both 
patients and carers. More than half of all stroke survivors are left dependent 
on others for everyday activities (1). Each year there are 110,000 first strokes 
and 30,000 recurrent strokes in the United Kingdom; 10,000 strokes occur in 
people younger than 65 and 60,000 people die of stroke. More than five per 
cent of NHS and social service resources are consumed by stroke patients (2). 
Finding an effective acute intervention for this burden, which is present 
worldwide, is proving challenging: aspirin has a wide utility but modest 
efficacy, and alteplase the converse; anticoagulation has proven ineffective (3) 
and various approaches with neuroprotection remain under investigation (4). 
In fact, with the exception of aspirin, thrombolytic therapy and 
hemicraniectomy, clinical management is primarily based on supportive care in 
a stroke unit (5-7). 
 
One potentially important area of development in the treatment of stroke is 
the use of stem cells to enhance recovery. The definition of a stem cell 
continues to evolve as more knowledge is gained on the subject. It currently 
requires demonstration of two properties: the capacity for self-renewal and the 
ability to differentiate into multiple cell types (potency) (8). A progenitor cell 
also has these characteristics but has a more restricted potential, i.e. it can 
only differentiate into a limited number of cell types and has a reduced 
capacity for self-renewal (8). Stem cell transplant trials are already underway 
in conditions such as diabetes, cancer, neurodegenerative disease (e.g. 
Parkinson’s Disease), and heart disease (9-12). This review describes the 
current situation with the use of stem cells in ischaemic stroke, with particular 
reference to haematopoietic stem cells. 
 
SOURCES OF STEM CELLS FOR STROKE THERAPY 
Although a commonly held belief that ‘the brain does not regenerate’, it is now 
accepted that spontaneous post-natal (adult) neurogenesis can occur (13). A 
number of cell sources for stem cell transplantation are available and these can 
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be categorised in several dimensions: exogenous or endogenous sources of 
cells; embryonic, foetal or adult derivation; neural or non-neural origin; and 
pluripotential (which can divide indefinitely) or multipotential (which usually 
regenerate their ‘own tissue’ but have the ability to transdifferentiate into 
other tissue cell types). 
 
Neural progenitor cells (NPCs) 
In both human and animal adult brain there are multiple sites of ongoing 
neuronal and glial formation. Human neural stem cells reside in the 
periventricular regions and cerebral cortex during development and have been 
shown to persist into adulthood in a number of sites including the dentate 
gyrus of the hippocampus, substantia nigra and olfactory bulb (13-17). Animal 
models demonstrate that ischaemic stroke is associated with differentiation of 
cells into neurons phenotypically similar to those lost in the ischaemic lesion 
(18), a finding suggesting that the adult brain has capacity for self repair. As 
observed in rodents, subventicular and hippocampal cells from adult human 
brain can be expanded in vitro, differentiate into all three neural cell lineages 
(neuronal, astrocytic and oligodendroglial) (19) and can improve functional 
recovery when administered intravenously into a rat model of stroke (20). 
Conflicting results have been seen with human foetal derived neural stem cells 
transplanted into stroke rats (21); though the cells were shown to migrate 
throughout the damaged striatum, cells within the transplant core were 
undifferentiated and of immature neural lineage. Virtually none of the grafted 
cells differentiated into astrocytes or oligodendrocytes. However, to date, there 
is no set of markers that precisely identifies a neural stem cell and 
distinguishes it from other more limited progenitors, precursors or 
differentiated cells. The isolation of true neural stem cells and the regions in 
which they exist remain under investigation. For example, cells cultured from 
areas outside of the striatal subventricular zone in the post-natal brain 
demonstrate a more limited capacity for self renewal than well characterised 
ventricular subependymal neural stem cells (22). The formal identification of 
cells as neural stem cells still requires functional demonstration of 
multipotency, self-renewal and longevity.  
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Embryonic and foetal stem cells  
Sufferers of Parkinson’s Disease appear to have benefited from human foetal 
stem cell transplantation (11), but these cells are in limited supply and their 
use is fraught with ethical issues in obtaining human tissue for the purpose of 
obtaining stem cells. Embryonic stem cells are capable of producing large 
quantities of neural progenitors and, in principle, are pluripotent with unlimited 
expandability; murine embryonic stem cells have been observed to 
differentiate into neurons and glial cells when grafted into stroke rats (23, 24) 
and survive for up to 12 weeks. A potential drawback is that they tend to 
develop a heterogeneous mix of neural precursors and differentiated neurons 
or glia as well as residual stem cells and a small percentage of non-neural cells 
(25); the challenge here is to direct differentiation into producing a 
homogenous cell population. Another disadvantage is their potential for 
malignant transformation. For example, when undifferentiated murine 
embryonic stem cells were xenotransplanted into a rat model of stroke, 
neuronal differentiation was observed; when the same cells were transplanted 
into the homologous mouse brain, the cells did not migrate and they produced 
a highly malignant teratocarcinoma (26). 
 
Porcine foetal cells 
Patients with Parkinson’s Disease and Huntington’s Disease have undergone 
stem cell transplantation with foetal porcine neurons (27, 28) and this donor 
source is considered as relatively safe. However, the insertion of foreign cells 
brings the risk of rejection and the need for chronic immunosuppression. 
Furthermore, xenotransplantation may lead to transmission of porcine viruses, 
such as the porcine endogenous retrovirus, although one study did not find 
any evidence of this problem (29). 
 
Immortalised cell lines 
Cells derived by either genetic transformation or cultured embryonic and adult 
tissue offer a ready and unlimited source of cells, thereby reducing ethical 
concerns in obtaining aborted foetal tissue. For example, LBS-Neurons (Layton 
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Bioscience, Inc) were produced from a NT2/D1 human precursor cell line and 
induced to differentiate into neurons by the addition of retinoic acid. This cell 
line was originally derived from a human testicular tumour more than 20 years 
ago (30) and the final product gives a neuronal cell population virtually 
indistinguishable from terminally differentiated post-mitotic neurons (31). 
Malignant transformation following therapeutic transplantation of this cell type 
is a key concern for this approach. 
 
Stem cells derived from the blood and bone marrow 
Bone marrow stromal cells, umbilical cord blood and peripheral blood stem 
cells (PBSCs) are alternative sources of stem cell and their use carries minimal 
ethical unease when transplanted in an autologous manner. Bone marrow and 
umbilical cord blood are composed of multiple cell types containing 
haematopoietic and endothelial precursors (CD34+ cells) and non-
haematopoietic cells (mesenchymal stromal or CD34- cells). Approximately 10-
20% of bone marrow derived stem cells (BMSCs) are multipotent, with the 
remaining representing more differentiated committed cells (32). It is 
contentious whether these latter cells can transdifferentiate into neural cells; 
bone marrow derived cells can adopt neural characteristics (33-35) but the 
cells are atypical (spherical in nature with few processes (36)) and it is argued 
that transplanted cells spontaneously fuse with recipient cells and 
subsequently adopt their phenotype (37). Additionally, murine haematopoietic 
stem cells demonstrate an age-dependent dimunition of self-renewal, 
increased apoptosis and functional exhaustion under conditions of stress (38). 
Nevertheless, bone marrow derived stem cells improved outcome in 
experimental models of stroke (39, 40), and preserved cognitive function has 
also been seen with intravenous transplantation of mesenchymal stem cells 
into rat models of Middle Cerebral Artery occlusion (MCAo) (41). Similarly, 
behavioural and neurological improvement has been demonstrated with 
intravenous infusion of CD133+ cells in stroke rats (42); the stem cell marker 
CD133, a transmembrane cell surface antigen, is specifically expressed on 30-
75% of CD34+ cells and has potential benefit for stem cell transplantation 
since they are less differentiated. However, in this particular study (42), 
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behavioural improvement was only apparent using intravenous transplantation 
within 1 hour of the stroke (compared to delivery at 3 days post stroke) and 
reduction of cerebral infarct size was only seen when the cells were 
transplanted intracerebrally. 
 
Haematopoietic stem cells (CD34+ cells) 
Haematopoietic stem cells (HSCs) are adult stem cells (the origins of which are 
poorly understood) that give rise to all blood cell types including myeloid and 
lymphoid lineages. The CD34 molecule is a cell surface glycoprotein expressed 
on HSCs and used to facilitate their identification, though CD34-ve HSCs may 
exist (43). An ischaemic stroke leads to mobilisation of CD34+ cells (as also 
seen in myocardial infarction (44)), which occurs in bursts over the first 10 
days post stroke (45, 46); those with higher levels of CD34+ cell mobilisation 
have a better neurological outcome (45). The origin and fate of these cells are 
not known. Interestingly, circulating CD34+ counts are inversely related to 
subsequent recurrent cerebral infarction (47) and cardiovascular events (48). 
Considering these changes, it is reasonable to hypothesis that promoting the 
mobilisation of CD34+ cells may be of therapeutic benefit. In one recent study, 
mononuclear cells were isolated and cultured ex vivo from the peripheral blood 
of 30 acute stroke patients (49). These ‘outgrowth’ cells demonstrated a 
heterogenous population of cells with endothelial and neuronal morphologies; 
the neuronal outgrowth cells, transplanted 4 days post ischaemia into rat 
brains, survived (for over 6 months), differentiated into neuronal phenotypes 
and helped improve functional recovery. 
 
Mobilisation of stem cells 
Production of stem cells derived from the bone marrow are stimulated by 
hormones called colony stimulating factors (CSFs). Stem cell factor (SCF) 
regulates differentiation of CD34+ stem cells; granulocyte-colony stimulating 
factor (G-CSF) – neutrophils; erythropoietin (EPO) – red blood cells; 
granulocyte-macrophage-colony stimulating factor (GM-CSF) – macrophages 
and neutrophils; macrophage-colony stimulating factor (M-CSF or CSF-1) – 
monocytes; and thrombopoietin (TPO) – platelets. SCF, G-CSF, EPO, GM-CSF 
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and M-CSF have all been evaluated in pre-clinical models of ischaemic stroke 
(50-54); studies using G-CSF and EPO have advanced to human stroke trials. 
 
Granulocyte-colony stimulating factor (G-CSF) 
Intentional recruitment of haematopoietic CD34+ stem cells from bone marrow 
to peripheral blood with G-CSF is a clinical process termed peripheral blood 
stem cell (PBSC) mobilisation. Although the mechanism involved in this 
process is largely unknown, G-CSF alone or with chemotherapy is used 
routinely in clinical practice to reduce the duration of neutropenia in patients 
with haematological disease, or for mobilising and harvesting PBSCs for 
subsequent autologous or allogenic infusion. Its use in stroke is novel and 
under investigation in both animals and humans. For therapeutic purposes, 
autologous marrow stem cells could be obtained but this is unattractive in view 
of the need for multiple marrow punctures.  
 
In rat and mice models of ischaemic stroke, a number of groups have 
demonstrated G-CSF to be neuroprotective at various doses (55), in the 
presence of thrombolysis (56, 57), induce functional recovery (52, 58) and 
promote angiogenesis (58-60) and neurogenesis (58, 60, 61). All have 
illustrated that G-CSF causes a reduction in stroke lesion volume. However, G-
CSF can also lead to impaired behavioural function (62) and may have no 
benefit when given in the chronic phase of stroke (63) or in global ischaemic 
models (64). 
 
The mechanisms of action of G-CSF are probably multimodal. Angiogenesis 
and neurogenesis may occur secondary to CD34+ cell mobilisation but further 
work on the effects of G-CSF reveal that neurons and adult neural stem cells 
express a G-CSF receptor and its expression is induced by ischaemia (61). Pre-
clinical studies also show that G-CSF may have an anti-inflammatory role as it 
causes suppression of iNOS (65) and other inflammatory mediators such as 
interleukin-1 beta (66). It is thought that the neuroprotective effect of G-CSF 
is mediated by anti-apoptotic activity via up-regulation of Stat 3 (signal 
CONFIDENTIAL Re-submission 12/5/8 
Page 8 of 26 
transducer and activator of transcription 3) and the JAK/STAT signaling 
pathway (65).  
 
MECHANISMS OF RECOVERY AFTER STROKE 
Motor, sensory and cognitive dysfunction are common results of stroke and 
cause considerable disability and social distress. Restoration of movement and 
motor function forms the focus of rehabilitation based on physical therapy. 
Recovery of motor and cognitive function occurs to a variable degree through a 
number of pathways (67-71): unmasking – recruitment of existing but latent 
connections; sprouting – development of new neural connections (including 
synaptogenesis); long term potentiation – enhancement of memory and 
learning; resolution of diaschisis (remote functional depression); and 
neurogenesis – replacing lost neurones. Additionally, animal models of 
recovery of function after stroke reveal that repetitive practice or exercise can 
evoke endogenous neurogenesis and the expression of signalling molecules 
(perhaps better called ‘regenokines’) such as brain derived neurotrophic factor 
(BDNF), which then promotes neuronal repair, enhancing learning and memory 
(72). 
 
There is increasing interest in the use of interventions that might augment 
these normal restorative events after stroke, either pharmacologically with 
drugs such as amphetamine (‘rehabilitation pharmacology’) (73) or, more 
recently, through the use of stem cells. Advances in molecular biology are 
creating opportunities to use cellular therapies to enhance neuronal 
regeneration in adjunct to a neuro-rehabilitation programme. However, the 
mechanism by which stem cells may improve recovery is still poorly 
understood. There are two theories: neuroprotection - preventing damaged 
neurons undergoing cell death in the acute phase of cerebral ischaemia; and 
neurorepair - the repair of broken neuronal networks in the chronic phase of 
cerebral ischaemia. When considering how stem cells promote recovery, there 
is probably some overlap between these two groups.  
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Reduced apoptosis and inflammation 
An intervention that reduces stroke lesion size, usually by decreasing cell 
death within the ischaemic penumbra, indicates neuroprotective activity. This 
mechanism has been demonstrated with intravenous administration of 
haematopoietic stem cells and via intracerebral grafting of human neural stem 
cells in ischaemic stroke models (74, 75). However, a reduction in lesion 
volume is not always seen with transplantation of stem cells from a variety of 
sources (39, 76-78), this perhaps relating to the method and time of 
administration post stroke. 
 
Neuroprotection could also be secondary to reducing inflammatory responses. 
It is likely that stem cells play a pivotal role in the regulation of the 
inflammatory cascade via the production of cytokines and growth factors and it 
might be expected that a cell transplant would induce or exacerbate 
inflammation. An exaggerated inflammatory response in the peri-infarct area 
has been observed in a murine model of stroke treated with G-CSF (62). 
Conversely, the use of human cord blood cells in a rat model of stroke had the 
opposite effect by decreasing the inflammatory infiltrate as indicated by a 
reduction in the expression of pro-inflammatory cytokines (79).  
 
Recruitment of endogenous neural progenitor cells (NPC) 
Since progenitor cells exist within the brain, and neurones, glia and vascular 
cells can be renewed, it might be thought that significant neurogenesis might 
take place after stroke. Although there are a number of rodent models 
investigating endogenous neurogenesis in cerebrovascular disease (80-82), 
few studies have been reported in humans. In one, histological examination 
was performed in an 84 year old patient who suffered a stroke 1 week prior to 
death (83). Using a neural stem cell label, large numbers of neural stem cells, 
vascular endothelial growth factor-immunopositive cells, and new blood vessels 
around the region of infarction were present suggesting the presence of 
ischaemia induced NPC recruitment and neovascularisation. Other studies have 
also shown the presence of ischaemia-induced endogenous neurogenesis (18). 
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Growth factors such as BDNF and nerve growth factor (NGF) are involved in 
the regulation of brain stem cell division and differentiation. Enhancing these 
naturally occurring neurogenic factors through exogenous administration offers 
a potential treatment for stroke. However, only one molecule has been tested 
to date; in a phase II/III trial (286 patients) of basic fibroblast growth factor 
(bFGF), treatment was ineffective, even showing a trend to hazard, and caused 
leucocytosis and hypotension (84). The use of treatments targeting a single 
growth factor pathway in pathophysiological states might have limited effect, 
as has been seen with numerous neuroprotectants with unimodal mechanisms 
of action (85). Stem cells offer a potential multimodal mechanism of action, 
including recruitment of endogenous progenitor cells via secretion of growth 
factors. 
 
Neurogenesis 
Whether stem cells can improve recovery by replication and differentiation 
(‘direct neurogenesis’), and thereby replace damaged brain cells and 
reconstruct neural circuitry, remains unclear with limited and conflicting 
evidence. In rats with induced MCAo, transplanted neurospheres survived 4 
weeks post transplant with the majority of migrating cells expressing a 
neuronal phenotype (including doublecortin, -tubulin and glial fibrillary acid 
protein [GFAP] markers) (76). Neurospheres derived from adult stroke rats can 
also differentiate into glia (as well as neurons), and can migrate towards the 
ischaemic lesion (86). A human neural stem cell line (CTX0E03, ReNeuron 
Group plc (87)), derived from human somatic stem cells following genetic 
modification with an immortalising gene, can differentiate into neurons and 
astrocytes, and induce significant improvements in both sensorimotor and 
gross motor function in the rat MCAO model of stroke 6 to 12 weeks post 
grafting (88). Finally, in mice incapable of developing cells of the myeloid and 
lymphoid lineages, transplanted adult bone marrow cells (BMCs) migrated into 
the brain and differentiated into cells that expressed neuron specific antigens 
(NeuN, a nuclear protein that is found exclusively in neurons) (34). In 
contrast, no evidence of neural-like cells was found in another study of mice 
transplanted with BMCs (89). Other groups have also failed to detect 
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differentiation of haematopoietic stem cells into neural tissue (90). In fact, in 
the positive studies showing cell differentiation into a neural phenotype, only 
small numbers of cells survived suggesting that integration into host circuitry 
is not the only or main mechanism of action to enhance functional recovery. 
Nevertheless, the finding that response may depend on the number of cells 
administered (‘dose response’) is compatible with beneficial effects being 
mediated by cell replacement (91).  
 
Angiogenesis 
Neurogenesis alone will not lead to recovery since neurones need nutritional 
support from the vasculature and new vessels will need to develop. 
Angiogenesis has been found experimentally, as shown when bone marrow-
derived CD34+ cells were administered intravenously to mice 48 hours after 
stroke induction (74); accelerated neovascularisation occurred in comparison 
with mice injected with CD34- cells. Furthermore, administration of an 
antiangiogenic agent prevented the beneficial effect of CD34+ precursors (74). 
While angiogenesis could reflect differentiation of haematopoietic stem cells 
into blood vessel wall cells, an indirect effect is also likely since human CD34+ 
cells have been shown to secrete numerous angiogenic factors, including 
vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF-
1) (92). Hence, a rich vascular environment mediated by CD34+ cells might 
enhance subsequent neuronal regeneration.  
 
Plasticity 
Neuroplasticity refers to organisational changes in the brain so that individual 
neurones or networks adapt their function. This theory forms the basis for 
goal-directed, therapeutic rehabilitation. Stem cells may augment this process 
via various mechanisms of recovery, including sprouting and unmasking, but 
the evidence in stroke remains limited. Sprouting has been seen in 
experimental stroke following intravenous administration of human bone 
marrow stromal cells to rats; a 50% reduction in lesion volume was seen in 
comparison to saline-treated controls (93). In contrast to this, treatment with 
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human umbilical cord blood cells did not improve sensorimotor or cognitive 
outcome in stroke rats (78) in one of the few reported negative studies. 
 
Stem cell migration 
Several experimental paradigms have tested the fate of stem cells when not 
implanted directly into the site of injury. Under ischaemic conditions, 
transplanted bone marrow stromal cells selectively migrated to the ischaemic 
hemisphere of the damaged brain in rats (94) suggesting that the injured brain 
might specifically attract these cells. In one study, cultured embryonic cells 
(D3 cell line) were incubated with superparamagnetic iron-oxide nanoparticles 
(to confer visibility with magnetic resonance imaging [MRI]) and then grafted 
into the normal hemisphere of rats given transient MCA ischaemia 14 days 
earlier; contrast was tracked with T2* weighted MRI, which is highly sensitive 
to iron-label, and was seen to migrate to the ischaemic hemisphere by 3-7 
days and remain there for at least 20 days post implantation (95). In another 
study, G-CSF was given to normal human donors to mobilise peripheral blood 
stem cells, the CD34+ cells being extracted, separated immunomagnetically 
and labelled (96). The cells were then grafted into the normal hemisphere of 
rats given permanent MCAO ischaemia 7 days earlier. Cells were tracked by 
T2* MRI migrating to the lesion side with label remaining for at least 21-50 
days (96). Furthermore, human cells were present in the lesion, corpus 
callosum and subventricular zone when assessed by immunohistochemistry. 
Uncertainty remains with the processes behind stem cell migration though 
some inroads have been made. For example, it appears that stromal cell 
derived factor–1alpha (SDF-1alpha) and its receptor CXCR4 play an important 
role in the migration of intravenously transplanted MSCs (97). 
 
CLINICAL TRIALS OF STEM CELL TRANSPLANTATION AFTER STROKE 
There have been no large-scale clinical trials of stem cell transplantation in 
stroke. However, a number of safety studies have been reported (see table 1). 
 
In one non-controlled study, cultured neuronal cells, derived from an 
immortalised cell-line (LBS-Neurons), were transplanted into 12 patients (age 
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44-75) with stroke (primarily involving basal ganglia) (98). Patients received 
one of 2 doses of cells via CT-guided, stereotactic-targeting of cell implants; 
immunosuppression was covered with intravenous methylprednisolone (during 
surgery) and then cyclosporine for 8 weeks. Although functional outcome could 
not be assessed since the study was too small and had no control group, PET 
scanning in 6 patients showed increased metabolic activity, suggesting either 
cell viability or the presence of inflammatory cells (98). Interestingly, detailed 
histopathological study of the brain from one of the study patients who died at 
27 months after cell implantation identified survival of transplanted neuronal 
cells with no evidence of malignancy (99). The potential for de-differentiation 
of transplanted cells back to a malignant state is a theoretical concern with the 
use of transformed stem cells derived from tumours, although pre-clinical 
studies in mice with this cell line (NT2) have demonstrated no toxicity or 
tumourgenicity (100).  
 
As a follow up to this study, the same researchers performed a phase two 
randomised trial, using the same cell line, in 18 patients (101). Patients were 
between 18 and 75 years and had a fixed motor deficit that was stable for at 
least 2 months. The treated group (n=14) received one of two doses of 
implanted cell and a rehabilitation programme; the control group (n=4) had 
rehabilitation alone. The primary outcome measure, the change in the 
European Stroke Scale motor score at 6 months, did not differ between the 
two groups (101). 
 
A safety and feasibility study of the use of foetal porcine cells in patients 1.5-
10 years after a middle cerebral artery infarct (affecting the striatum) has also 
recently been performed (102). To prevent rejection, cells were pre-treated 
with anti-MHC1 antibody and no immunosuppressive drugs were given to the 
patients. Of the 12 planned patients, only 5 patients entered the study 
following which the US Federal Drug Administration halted the trial 
prematurely after 2 patients developed serious adverse events. One patient 
suffered a cortical vein occlusion secondary to the surgical procedure, and the 
other experienced generalised and partial seizures while hyperglycaemic. 
CONFIDENTIAL Re-submission 12/5/8 
Page 14 of 26 
These observations highlight the potential risks with intracranial 
transplantation of stem cells and suggest that other modes of delivery of stem 
cells should be considered.  
 
One such alternative is to use autologous stem cells. A recent randomised 
controlled trial tested mysenchymal stem cells (MSCs) in patients with middle 
cerebral artery territory infarction (103). 5 patients with persistent 
neurological deficit 7 days after their ischaemic stroke were allocated to 
receive intravenous MSCs and 25 patients acted as controls (no additional 
intervention and no sham procedure). MSCs were acquired from bone marrow 
aspirates and then cultured ex vivo to obtain sufficient quantities before re-
injection into the patient 4-6 and then 7-9 weeks after symptom onset. At 1 
year, 10 patients in the control group were lost to follow-up but no serious 
adverse events such as infection or tumour formation had occurred. The study 
has demonstrated feasibility in administering ex-vivo cultured MSCs but the 
authors have been heavily criticised for both its methods and conclusions 
reached (104) and have since issued an apology for having plagiarised sections 
of their discussion (105). 
G-CSF in clinical stroke 
Three small, randomised controlled trials have assessed the safety of 
recombinant G-CSF after ischaemic stroke (table 2). A recently completed 
phase IIa dose-escalation trial assessed G-CSF in 36 patients (G-CSF, n=24; 
placebo, n=12) with sub-acute ischaemic stroke (106). Patients were treated 
between 7-30 days post ictus with increasing doses of G-CSF (1-10g/kg given 
either once or daily for 5 days) given subcutaneously. G-CSF increased 
circulating CD34+ counts 10-fold (as measured by flow cytometry) in a dose-
dependent manner and with the peak level occurring at day 5. A dose-
dependent increase in white cell count at day 3 and decrease in platelet count 
also occurred, expected effects of G-CSF. Serious adverse event rates did not 
differ although the frequency of infection was non-significantly higher in G-CSF 
treated patients (29% vs. 25%); stroke recurrence rates did not differ 
between the treatment groups. 
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In a second trial, 10 patients with a National Institutes of Health Stroke Scale 
(NIHSS) score between 9 and 20 and within 7 days of stroke onset were 
randomised to 5 days of G-CSF (15 µg/kg per day, n=7) or control (routine 
care, n=3) (107). Over a 12-month follow-up, patients who received G-CSF 
had a significantly greater improvement in neurological function and disability 
than control patients. There was no aggravation of stroke symptoms and no 
thrombotic complications. Unfortunately, the results are confounded since 
many patients receiving G-CSF had a lacunar infarction, a type of stroke that 
often improves spontaneously. In the third trial, 15 patients were randomized 
within 1 week of stroke onset to receive G-CSF and 30 to placebo (108). A 
non-significant reduction in NIHSS was noted at day 10, which became 
significant at day 20. 
 
In a Cochrane systematic review of the three trials of G-CSF (as well as other 
colony stimulating factors) for stroke, G-CSF did not significantly alter 
functional outcome although there was a trend to reduced impairment (109). 
Furthermore, G-CSF was well tolerated and appeared to be safe, and 
significantly increased white cell count (109). The long term safety of G-CSF 
has been monitored in 101 normal donors who had G-CSF for the purpose of 
mobilising PBSCs prior to allogenic transplantation; there were no obvious 
adverse effects over a 3-6 year follow-up period and, in particular, the rates of 
cancer and vascular disease were not increased (110). Nevertheless, G-CSF 
may cause a hypercoagulable state (111), a potential mechanism for 
increasing recurrent stroke rates. In healthy donors receiving G-CSF, in vitro 
bleeding time is decreased with increased levels of Factor VIII and fibrinogen, 
and reduced protein C and S activity (111). 
 
Further trials of G-CSF are underway including a dose-escalation (30-
180g/kg) study in acute ischaemic stroke (n=44), a trial in sub-acute stroke 
(n=60), and a trial in 40 patients with chronic stroke (3 months from ictus); a 
non-controlled study is also ongoing (109). Data from these completed and 
ongoing trials will inform whether larger phase III trials of G-CSF are 
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warranted. Although other colony stimulating factors such as stem cell factor 
(SCF), granulocyte-macrophage-colony stimulating factor (GM-CSF) and 
macrophage-colony stimulating factor (M-CSF or CSF-1) also mobilise bone 
marrow-derived stem cells (and recombinant forms are available), trials in 
patients with stroke have not been reported (109). 
 
FUTURE DEVELOPMENT OF STEM CELLS FOR THE TREATMENT OF 
STROKE 
Although many studies assessing stem cells in pre-clinical stroke have been 
reported, and limited clinical trial data are now available, many questions 
remain unanswered. There is also a noticeable lack of published studies 
reporting a negative or neutral outcome. This publication bias can perpetuate 
the development of inappropriate clinical trials that will not answer the 
uncertainties that remain in this field (112). It is vital that future experimental 
studies are of high quality (for example, conforming to the STAIR criteria 
(113)) and have standardised protocols and outcome measures so they can be 
fairly compared. 
 
One possible advantage of treating stroke with stem cells is a potentially wide 
therapeutic window. The optimal time of administration post stroke will relate 
to the micro-environment of the damaged area, i.e. should stem cells be 
administered during the acute phase of stroke at a time when inflammatory 
responses are maximal or will delayed treatment be effective at a time when 
scar tissue has formed? The inflammatory response can last up to several 
weeks and it may be that stem cells could exacerbate or attenuate this 
process. Relatively few studies have analysed the effects of stem cells in 
intracerebral haemorrhage (ICH) but a reduction in inflammation was observed 
in one study assessing intravenous human neural stem cells in experimental 
ICH (114); the majority of the transplanted cells were detected in the marginal 
zones of the spleen with only very few seen in the brain sections. Adipose 
derived stem cells (ASCs) have also been transplanted into experimental ICH 
(115), and again, a reduction in the inflammatory response was seen but ASCs 
did not reveal any evidence of neuronal transdifferentiation.  
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The ideal route of stem cell delivery is also unclear. This has been addressed in 
one pre-clinical study comparing intra-striatal, intra-ventricular and 
intravenous administration of neural precursor cells with all routes resulting in 
cells targeting the lesion (116). In contrast to this, another study assessing 
intravenous administration of human umbilical cord cells in stroke rats did not 
detect any evidence of stem cells in the target lesion (117). If intracerebral 
administration is the most effective (though probably the most hazardous) 
then should cells be transplanted directly into the ischaemic lesion or distant to 
it (reducing the chance of damaging vital structures) and relying on 
spontaneous stem cell migration (76, 95, 118)? Existing human safety trials 
used intracerebral injections of stem cells directly into the peri-infarct area 
(98, 101), a decision appearing not to be based on any substantial pre-clinical 
work. The role of immunosupression in such exogenous transplants also 
remains elusive.  
 
There are multiple sources of exogenous stem cells available (at least 5 types 
of adult stem cells are in commercial development (119)) and the cell type 
that should be transplanted for a given stroke type and size is undetermined. 
Endogenous stem cell treatment is an attractive alternative, removing the 
need for immunosuppression. CD34+ stem cells can be mobilised into 
peripheral blood with G-CSF in ischaemic stroke patients in a dose dependent 
manner (106), but it may be the direct neuroprotective qualities of G-CSF that 
play a more important role. G-CSF already possesses a good safety record and 
pharmacological profile for use in humans and, though it is essential that 
thorough pre-clinical work precede human clinical trials (pre-clinical data on 
ideal doses and times of administration of G-CSF are still outstanding), the use 
of G-CSF and other colony stimulating factors such as erythropoietin have 
progressed to phase II and III stroke trials.  
 
CONCLUSION 
There is much hope and hype attached to the development of stem cell 
therapies. However, many questions remain to be answered and patients 
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should not, at present, undergo stem cell therapy out with a properly designed 
randomised controlled trial. 
 
ACKNOWLEDGEMENTS 
TE is funded by the MRC; PM and PB are recipient of a grant on HSCs from 
ESRC; PB is a Stroke Association Professor of Stroke Medicine. TE and PB are 
running an MRC funded phase II trial assessing GCSF mobilisation of HSCs in 
ischaemic stroke. 
 
REFERENCES 
1. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, 
case fatality, and mortality for all acute vascular events in all arterial territories (Oxford 
Vascular Study). Lancet 2005;366(9499):1773-83. 
2. Bath PM, Lees KR. ABC of arterial and venous disease. Acute stroke. BMJ 
2000;320(7239):920-3. 
3. Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a 
randomised aspirin-controlled trial. Lancet 2001;358(9283):702-10. 
4. Ferro JM, Davalos A. Other neuroprotective therapies on trial in acute stroke. 
Cerebrovascular Diseases 2006;2:127-30. 
5. The ATLANTIS ECASS and NINDS rt-PA Study Group Investigators. Association of 
outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS 
rt-PA stroke trials. The Lancet 2004;363:768-813. 
6. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction 
of the middle cerebral artery: a pooled analysis of three randomised controlled trials.[see 
comment]. Lancet Neurology 2007;6(3):215-22. 
7. Stroke Unit Trialists C. Organised inpatient (stroke unit) care for stroke. Cochrane Database 
of Systematic Reviews. 2007((4):CD000197). 
8. Melton DA, Cowan C. "Stemness": Definitions, Criteria and Standards. In: Lanza R, editor. 
Handbook of Stem Cells. 1st ed. Burlington, San Diego, USA: Elsevier Academic Press; 
2004. p. xxv - xxxi. 
9. Burt R. Safety and efficacy study of autologous stem cell transplantation for early onset 
Type I Diabetes Mellitus. http://clinicaltrials.gov/ct/show/NCT00315133. Ongoing. 
10. NCI. Donor stem cell transplant in treating patients with hematological cancer. 
http://clinicaltrials.gov/ct/show/NCT00054327. Ongoing. 
11. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for 
severe Parkinson's disease. New England Journal of Medicine 2001;344(10):710-9. 
12. Stamm C, Kleine HD, Choi YH, et al. Intramyocardial delivery of CD133+ bone marrow 
cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and 
efficacy studies. Journal of Thoracic & Cardiovascular Surgery 2007;133(3):717-25. 
13. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human 
hippocampus. Nature Medicine 1998;4(11):1313-7. 
14. Roy NS, Wang S, Jiang L, et al. In vitro neurogenesis by progenitor cells isolated from the 
adult human hippocampus. Nature Medicine 2000;6(3):271-7. 
15. Richardson RM, Holloway KL, Bullock MR, Broaddus WC, Fillmore HL. Isolation of 
neuronal progenitor cells from the adult human neocortex. Acta Neurochirurgica 
2006;148(7):773-7. 
CONFIDENTIAL Re-submission 12/5/8 
Page 19 of 26 
16. Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mammalian 
substantia nigra. Proceedings of the National Academy of Sciences of the United States of 
America 2003;100(13):7925-30. 
17. Pagano SF, Impagnatiello F, Girelli M, et al. Isolation and characterization of neural stem 
cells from the adult human olfactory bulb. Stem Cells 2000;18(4):295-300. 
18. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from 
endogenous precursors in the adult brain after stroke. Nature Medicine 2002;8(9):963-70. 
19. Kukekov VG, Laywell ED, Suslov O, et al. Multipotent stem/progenitor cells with similar 
properties arise from two neurogenic regions of adult human brain. Experimental Neurology 
1999;156(2):333-44. 
20. Chu K, Kim M, Park KI, et al. Human neural stem cells improve sensorimotor deficits in the 
adult rat brain with experimental focal ischemia. Brain Research 2004;1016(2):145-53. 
21. Darsalia V, Kallur T, Kokaia Z. Survival, migration and neuronal differentiation of human 
fetal striatal and cortical neural stem cells grafted in stroke-damaged rat striatum. European 
Journal of Neuroscience 2007;26(3):605-14. 
22. Seaberg RM, Smukler SR, van der Kooy D. Intrinsic differences distinguish transiently 
neurogenic progenitors from neural stem cells in the early postnatal brain. Developmental 
Biology 2005;278(1):71-85. 
23. Buhnemann C, Scholz A, Bernreuther C, et al. Neuronal differentiation of transplanted 
embryonic stem cell-derived precursors in stroke lesions of adult rats. Brain 2006;129(Pt 
12):3238-48. 
24. Wei L, Cui L, Snider BJ, et al. Transplantation of embryonic stem cells overexpressing Bcl-
2 promotes functional recovery after transient cerebral ischemia. Neurobiology of Disease 
2005;19(1-2):183-93. 
25. Pollard S, Conti L, Smith A. Exploitation of adherent neural stem cells in basic and applied 
neurobiology. Regenerative Medicine 2006;1(1):111-118. 
26. Erdo F, Buhrle C, Blunk J, et al. Host-dependent tumorigenesis of embryonic stem cell 
transplantation in experimental stroke. Journal of Cerebral Blood Flow & Metabolism 
2003;23(7):780-5. 
27. Schumacher JM, Ellias SA, Palmer EP, et al. Transplantation of embryonic porcine 
mesencephalic tissue in patients with PD. Neurology 2000;54(5):1042-50. 
28. Dunnett SB, Rosser AE. Stem cell transplantation for Huntington's disease. Experimental 
Neurology 2007;203(2):279-92. 
29. Dinsmore JH, Manhart C, Raineri R, Jacoby DB, Moore A. No evidence for infection of 
human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal 
neuronal cells. Transplantation 2000;70(9):1382-9. 
30. Andrews PW, Damjanov I, Simon D, et al. Pluripotent embryonal carcinoma clones derived 
from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. 
Laboratory Investigation 1984;50(2):147-62. 
31. Trojanowski JQ, Kleppner SR, Hartley RS, et al. Transfectable and transplantable 
postmitotic human neurons: a potential "platform" for gene therapy of nervous system 
diseases. Experimental Neurology 1997;144(1):92-7. 
32. Bianco P, Robey G. Skeletal stem cells. In: Lanza R, editor. Handbook of stem cells. 1st ed. 
Burlington, San Diego, USA: Elsevier Academic Press; 2004. p. 415-4125. 
33. Sanchez-Ramos J, Song S, Cardozo-Pelaez F, et al. Adult bone marrow stromal cells 
differentiate into neural cells in vitro. Experimental Neurology 2000;164(2):247-56. 
34. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells 
bearing neuronal antigens generated in vivo from bone marrow. Science 
2000;290(5497):1779-82. 
35. Li Y, Chen J, Chopp M. Adult bone marrow transplantation after stroke in adult rats. Cell 
Transplantation 2001;10(1):31-40. 
CONFIDENTIAL Re-submission 12/5/8 
Page 20 of 26 
36. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow 
stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into 
the ischemic brain of rats. Experimental Neurology 2002;174(1):11-20. 
37. Terada N, Hamazaki T, Oka M, et al. Bone marrow cells adopt the phenotype of other cells 
by spontaneous cell fusion. Nature 2002;416(6880):542-5. 
38. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, Weissman IL. Deficiencies in 
DNA damage repair limit the function of haematopoietic stem cells with age. Nature 
2007;447(7145):725-9. 
39. Chen J, Sanberg PR, Li Y, et al. Intravenous administration of human umbilical cord blood 
reduces behavioral deficits after stroke in rats. Stroke 2001;32(11):2682-8. 
40. Nagai A, Kim WK, Lee HJ, et al. Multilineage potential of stable human mesenchymal stem 
cell line derived from fetal marrow. PLoS ONE [Electronic Resource] 2007;2(12):e1272. 
41. Sokolova I, Fedotova O, Zin'Kova N, Kruglyakov P, Polyntsev D. Effect of Mesenchymal 
Stem Cell Transplantation on Cognitive Function in Rats with Ischaemic Stroke. Cell 
Technologies in Biology and Medicine 2006;2(4):511-514. 
42. Borlongan CV, Evans A, Yu G, Hess DC. Limitations of intravenous human bone marrow 
CD133+ cell grafts in stroke rats. Brain Research 2005;1048(1-2):116-22. 
43. Guo Y, Lubbert M, Engelhardt M. CD34- hematopoietic stem cells: current concepts and 
controversies. Stem Cells 2003;21(1):15-20. 
44. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in 
patients with acute myocardial infarction. Circulation 2001;103(23):2776-9. 
45. Dunac A, Frelin C, Popolo-Blondeau M, Chatel M, Mahagne M, P P. Neurological and 
functional recovery in human stroke are associated with peripheral blood CD34+ cell 
mobilization. J Neurol 2007;254:327-332. 
46. Hennemann B, Ickenstein G, Sauerbruch S, et al. Mobilization of CD34+ hematopoietic 
cells, colony-forming cells and long-term culture-initiating cells into the peripheral blood of 
patients with an acute cerebral ischemic insult. Cytotherapy 2008;10(3):303-11. 
47. Taguchi A, Matsuyama T, Moriwaki H, et al. Circulating CD34-positive cells provide an 
index of cerebrovascular function. Circulation 2004;109(24):2972-5. 
48. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating 
endothelial progenitor cells predicts future cardiovascular events: proof of concept for the 
clinical importance of endogenous vascular repair. Circulation 2005;111(22):2981-7. 
49. Jung KH, Chu K, Lee ST, et al. Identification of neuronal outgrowth cells from peripheral 
blood of stroke patients. Annals of Neurology 2008;63(3):312-22. 
50. Jin K, Mao XO, Sun Y, Xie L, Greenberg DA. Stem cell factor stimulates neurogenesis in 
vitro and in vivo. Journal of Clinical Investigation 2002;110(3):311-9. 
51. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to 
protect against experimental brain injury. Proceedings of the National Academy of Sciences 
of the United States of America 2000;97(19):10526-31. 
52. Gibson CL, Bath PM, Murphy SP. G-CSF reduces infarct volume and improves functional 
outcome after transient focal cerebral ischemia in mice. Journal of Cerebral Blood Flow & 
Metabolism 2005;25(4):431-9. 
53. Schabitz WR, Kruger C, Pitzer C, et al. A neuroprotective function for the hematopoietic 
protein granulocyte-macrophage colony stimulating factor (GM-CSF). Journal of Cerebral 
Blood Flow & Metabolism 2008;28(1):29-43. 
54. Vincent VA, Robinson CC, Simsek D, Murphy GM. Macrophage colony stimulating factor 
prevents NMDA-induced neuronal death in hippocampal organotypic cultures. Journal of 
Neurochemistry 2002;82(6):1388-97. 
55. Schabitz WR, Kollmar R, Schwaninger M, et al. Neuroprotective effect of granulocyte 
colony-stimulating factor after focal cerebral ischemia. Stroke 2003;34(3):745-51. 
CONFIDENTIAL Re-submission 12/5/8 
Page 21 of 26 
56. Kollmar R, Henninger N, Urbanek C, Schabitz W, Schneider A, Schwab S. Effects of G-
CSF in combination with rt-PA after experimental thromboembolic stroke. Akt Neurol 
2004;31. 
57. Kollmar R, Henninger N, Urbanek C, Schwab S. G-CSF and rt-PA for the treatment of 
Experimental Embolic Stroke. Cerebrovascular Diseases 2007;23(Suppl 2):23. 
58. Shyu WC, Lin SZ, Yang HI, et al. Functional recovery of stroke rats induced by granulocyte 
colony-stimulating factor-stimulated stem cells. Circulation 2004;110(13):1847-54. 
59. Lee ST, Chu K, Jung KH, et al. Granulocyte colony-stimulating factor enhances 
angiogenesis after focal cerebral ischemia. Brain Research 2005;1058:120-128. 
60. Sehara Y, Hayashi T, Deguchi K, et al. Potentiation of neurogenesis and angiogenesis by G-
CSF after focal cerebral ischemia in rats. Brain Research 2007;1151:142-9. 
61. Schneider A, Kruger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal 
ligand that counteracts programmed cell death and drives neurogenesis. Journal of Clinical 
Investigation 2005;115(8):2083-98. 
62. Taguchi A, Wen Z, Myojin K, et al. Granulocyte colony-stimulating factor has a negative 
effect on stroke outcome in a murine modelwa. European Journal of Neuroscience 
2007;26(1):126-33. 
63. Zhao LR, Berra HH, Duan WM, et al. Beneficial effects of hematopoietic growth factor 
therapy in chronic ischemic stroke in rats. Stroke 2007;38(10):2804-11. 
64. Matchett GA, Calinisan JB, Matchett GC, Martin RD, Zhang JH. The effect of granulocyte-
colony stimulating factor in global cerebral ischemia in rats. Brain Research 
2007;1136(1):200-7. 
65. Komine-Kobayashi M, Zhang N, Liu M, et al. Neuroprotective effect of recombinant human 
granulocyte colony-stimulating factor in transient focal ischemia of mice. Journal of 
Cerebral Blood Flow & Metabolism 2006;26(3):402-13. 
66. Gibson CL, Jones NC, Prior MJ, Bath PM, Murphy SP. G-CSF suppresses edema formation 
and reduces interleukin-1beta expression after cerebral ischemia in mice. Journal of 
Neuropathology & Experimental Neurology 2005;64(9):763-9. 
67. Jacobs KM, Donoghue JP. Reshaping the cortical motor map by unmasking latent 
intracortical connections. Science 1991;251(4996):944-7. 
68. Carmichael ST, Chesselet MF. Synchronous neuronal activity is a signal for axonal 
sprouting after cortical lesions in the adult. Journal of Neuroscience 2002;22(14):6062-70. 
69. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the 
hippocampus. Nature 1993;361(6407):31-9. 
70. Pantano P, Baron JC, Samson Y, Bousser MG, Derouesne C, Comar D. Crossed cerebellar 
diaschisis. Further studies. Brain 1986;109(Pt 4):677-94. 
71. Jin K, Minami M, Lan JQ, et al. Neurogenesis in dentate subgranular zone and rostral 
subventricular zone after focal cerebral ischemia in the rat. Proceedings of the National 
Academy of Sciences of the United States of America 2001;98(8):4710-5. 
72. Vaynman S, Gomez-Pinilla F. License to run: exercise impacts functional plasticity in the 
intact and injured central nervous system by using neurotrophins. Neurorehabilitation & 
Neural Repair 2005;19(4):283-95. 
73. Sprigg N, Bath P. Pharmacological enhancement of recovery from stroke. Current Medical 
Literature Stroke Review 2005;8(2):33-39. 
74. Taguchi A, Soma T, Tanaka H, et al. Administration of CD34+ cells after stroke enhances 
neurogenesis via angiogenesis in a mouse model. Journal of Clinical Investigation 
2004;114(3):330-8. 
75. Ishibashi S, Sakaguchi M, Kuroiwa T, et al. Human neural stem/progenitor cells, expanded 
in long-term neurosphere culture, promote functional recovery after focal ischemia in 
Mongolian gerbils. Journal of Neuroscience Research 2004;78(2):215-23. 
CONFIDENTIAL Re-submission 12/5/8 
Page 22 of 26 
76. Kelly S, Bliss TM, Shah AK, et al. Transplanted human fetal neural stem cells survive, 
migrate, and differentiate in ischemic rat cerebral cortex. Proceedings of the National 
Academy of Sciences of the United States of America 2004;101(32):11839-44. 
77. Nystedt J, Makinen S, Laine J, Jolkkonen J. Human cord blood CD34+ cells and behavioral 
recovery following focal cerebral ischemia in rats. Acta Neurobiologiae Experimentalis 
2006;66(4):293-300. 
78. Makinen S, Kekarainen T, Nystedt J, et al. Human umbilical cord blood cells do not 
improve sensorimotor or cognitive outcome following transient middle cerebral artery 
occlusion in rats. Brain Research 2006;1123(1):207-15. 
79. Vendrame M, Gemma C, de Mesquita D, et al. Anti-inflammatory effects of human cord 
blood cells in a rat model of stroke. Stem Cells & Development 2005;14(5):595-604. 
80. Lee SH, Kim YJ, Lee KM, Ryu S, Yoon BW. Ischemic preconditioning enhances 
neurogenesis in the subventricular zone. Neuroscience 2007;146(3):1020-31. 
81. Ray J, Gage FH. Differential properties of adult rat and mouse brain-derived neural 
stem/progenitor cells. Molecular & Cellular Neurosciences 2006;31(3):560-73. 
82. Yagita Y, Kitagawa K, Ohtsuki T, et al. Neurogenesis by progenitor cells in the ischemic 
adult rat hippocampus. Stroke 2001;32(8):1890-6. 
83. Minger S, Ekonomou A, Carta E, Chinoy A, Perry R, Ballard C. Endogenous neurogenesis 
in the human brain following cerebral infarction. Regenerative Medicine 2007;2(1):69-74. 
84. Bogousslavsky J, Victor S, Salinas E, et al. Fiblast (Trafermin) in acute stroke: results of the 
European-Australian phase II/III safety and efficacy trial. Cerebrovascular Diseases 
2002;14:239-251. 
85. Lees KR, Muir KW. Excitatory amino acid antagonists for acute stroke (Cochrane Review). 
In: The Cochrane Library. In press ed. Oxford: Update Software; 2002. 
86. Zhang R, Zhang Z, Wang L, et al. Activated neural stem cells contribute to stroke-induced 
neurogenesis and neuroblast migration toward the infarct boundary in adult rats. Journal of 
Cerebral Blood Flow & Metabolism 2004;24(4):441-8. 
87. Sinden JD. ReNeuron Group plc. Regenerative Medicine 2006;1(1):143-147. 
88. Pollock K, Stroemer P, Patel S, et al. A conditionally immortal clonal stem cell line from 
human cortical neuroepithelium for the treatment of ischemic stroke. Experimental 
Neurology 2006;199(1):143-55. 
89. Castro RF, Jackson KA, Goodell MA, Robertson CS, Liu H, Shine HD. Failure of bone 
marrow cells to transdifferentiate into neural cells in vivo. Science 2002;297(5585):1299. 
90. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental 
plasticity of adult hematopoietic stem cells.[see comment]. Science 2002;297(5590):2256-9. 
91. Vendrame M, Cassady J, Newcomb J, et al. Infusion of human umbilical cord blood cells in 
a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct 
volume. Stroke 2004;35(10):2390-5. 
92. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Numerous growth factors, cytokines, 
and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and 
megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. 
Blood 2001;97(10):3075-85. 
93. Xiao J, Nan Z, Motooka Y, Low WC. Transplantation of a novel cell line population of 
umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic 
brain injury. Stem Cells & Development 2005;14(6):722-33. 
94. Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone 
marrow stromal cells after cerebral ischemia in rats. Stroke 2001;32(4):1005-11. 
95. Hoehn M, Kustermann E, Blunk J, et al. Monitoring of implanted stem cell migration in 
vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental 
stroke in rat. Proceedings of the National Academy of Sciences of the United States of 
America 2002;99(25):16267-72. 
CONFIDENTIAL Re-submission 12/5/8 
Page 23 of 26 
96. Jendelova P, Herynek V, Urdzikova L, et al. Magnetic resonance tracking of human CD34 
progenitor cells separated by means of immunomagnetic selection and transplanted into 
injured rat brain. Cell Transplantation 2005;14:173-182. 
97. Wang Y, Deng Y, Zhou GQ. SDF-1alpha/CXCR4-mediated migration of systemically 
transplanted bone marrow stromal cells towards ischemic brain lesion in a rat model. Brain 
Research 2008;1195:104-12. 
98. Kondziolka D, Wechsler L, Goldstein S, et al. Transplantation of cultured human neuronal 
cells for patients with stroke. Neurology 2000;55(4):565-9. 
99. Nelson PT, Kondziolka D, Wechsler L, et al. Clonal human (hNT) neuron grafts for stroke 
therapy: neuropathology in a patient 27 months after implantation. American Journal of 
Pathology 2002;160(4):1201-6. 
100. Kleppner SR, Robinson KA, Trojanowski JQ, Lee VM. Transplanted human neurons 
derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 
year in the nude mouse brain. Journal of Comparative Neurology 1995;357(4):618-32. 
101. Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplantation for patients with 
subcortical motor stroke: a phase 2 randomized trial. Journal of Neurosurgery 
2005;103(1):38-45. 
102. Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR. Neurotransplantation of 
fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility 
study. Cerebrovascular Diseases 2005;20(2):101-7. 
103. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in 
stroke patients. Annals of Neurology 2005;57(6):874-82. 
104. De Keyser J. Autologous mesenchymal stem cell transplantation in stroke 
patients.[comment]. Annals of Neurology 2005;58(4):653-4; author reply 654-5. 
105. Bang OY. An apology: inadvertent error in our article published in June 2005 issue of the 
Annals of Neurology (Ann Neurol 2005;57:874-882). Annals of Neurology 2005;58(4):659. 
106. Sprigg N, Bath PM, Zhao L, et al. Granulocyte-colony-stimulating factor mobilizes bone 
marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery 
EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). 
Stroke 2006;37(12):2979-83. 
107. Shyu WC, Lin SZ, Lee CC, Liu DD, Li H. Granulocyte colony-stimulating factor for acute 
ischemic stroke: a randomized controlled trial. CMAJ Canadian Medical Association 
Journal 2006;174(7):927-33. 
108. Zhang JJ, Deng M, Zhang Y, Sui W, Wang L, Sun A. A Short-Term Assessment of 
Recombinant Granulocyte-Stimulating factor (RHG-CSF) in Treatment of Acute Cerebral 
Infarction. Cerebrovascular Diseases 2006;21(Suppl 4):143. 
109. Bath PM, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte 
colony stimulating factor and analogues) for stroke. Cochrane Database of Systematic 
Reviews 2006;3:CD005207. 
110. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors 
who received recombinant human granulocyte colony-stimulating factor. Bone Marrow 
Transplantation 2000;25(1):85-9. 
111. Sohngen D, Wienen S, Siebler M, et al. Analysis of rhG-CSF-effects on platelets by in vitro 
bleeding test and transcranial Doppler ultrasound examination. Bone Marrow Transplant 
1998;22:1087-1090. 
112. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. 
JAMA 2005;294(2):218-28. 
113. Anonymous. Recommendations for standards regarding preclinical neuroprotective and 
restorative drug development. Stroke 1999;30(12):2752-8. 
114. Lee ST, Chu K, Jung KH, et al. Anti-inflammatory mechanism of intravascular neural stem 
cell transplantation in haemorrhagic stroke. Brain 2008;131(Pt 3):616-29. 
CONFIDENTIAL Re-submission 12/5/8 
Page 24 of 26 
115. Kim JM, Lee ST, Chu K, et al. Systemic transplantation of human adipose stem cells 
attenuated cerebral inflammation and degeneration in a hemorrhagic stroke model. Brain 
Research 2007;1183:43-50. 
116. Jin K, Sun Y, Xie L, et al. Comparison of ischemia-directed migration of neural precursor 
cells after intrastriatal, intraventricular, or intravenous transplantation in the rat. 
Neurobiology of Disease 2005;18(2):366-74. 
117. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of 
peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. 
Stroke 2004;35(10):2385-9. 
118. Modo M, Mellodew K, Cash D, et al. Mapping transplanted stem cell migration after a 
stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage 2004;21(1):311-7. 
119. Martin PA, Coveney C, Kraft A, Brown N, Bath P. Commercial Development of Stem Cell 
Technology: Lessons from the Past, Strategies for the Future. Regenerative Medicine 
2006;1(6):801-807. 
 
 
CONFIDENTIAL Re-submission 12/5/8 
Page 25 of 26 
 
 
Table 1. Summary of observational and randomised controlled trials involving stem cells after stroke 
 
Author, 
year 
Cells Patients  
(active / 
control) 
Stroke type Administration Immunosuppression Comments 
Kondziolka   
2000 (98) 
Immortalised 
neuronal 
12 / 0 Basal ganglia 
infarct 
Stereotactic 
transplantation 
into region of the 
stroke 
Methylprednisolone 
during surgery. 
Cyclosporine 1 week 
prior to surgery and 
continued for 8 weeks 
No effect on functional 
outcome. PET showed 
increased metabolic 
activity. 
Kondziolka  
2005 (101) 
Immortalised 
neuronal 
14 / 4 Basal ganglia 
infarct 
Stereotactic 
transplantation 
into region of the 
stroke 
Methylprednisolone 
during surgery. 
Cyclosporine 1 week 
prior to surgery and 
continued for 6 months 
No effect on functional 
outcome. 
Savitz 
2005 (102) 
Foetal porcine 5 (of planned 
12) / 0 
MCA infarct Stereotactic 
transplantation 
into region of the 
stroke 
None (cells pre-treated 
with anti-MHC antibody) 
Study stopped early 
after 2 SAEs 
Bang 2005 
(103) 
Autologous, 
mysenchymal 
5 / 25 MCA infarct Intravenous None Questionable study 
quality, e.g. 10 
patients lost to follow-
up 
MCA Middle Cerebral Artery; SAE Serious Adverse Event; BI Barthel Index 
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Table 2. Summary of human clinical trials in G-CSF and ischaemic stroke 
 
Author / year Trial Design G-CSF Regimen Time after 
stroke 
Patients 
(active / 
control) 
Comments 
Shyu 2006 
(107) 
Single-blind 
controlled 
15µg/kg/day s/c 
For 5 days 
Within 7 days 7 / 3 No thrombotic complications. 
Improved outcome in G-CSF 
group but a majority of 
lacunar strokes 
Sprigg 2006 
(106) 
Double-blind 
placebo-controlled 
Dose escalation 
1-10µg/kg s/c 
For 1 or 5 days 
7-30 days post 
ictus 
24 / 12 No difference in SAEs 
although non-significant 
increase in infection rates in 
active group 
Zhang 2006 
(108) 
Double-blind 
placebo-controlled 
2 µg/kg/day s/c 
For 5 days 
Within 7 days 15 / 45 No difference in adverse 
events reported. Significant 
reduction in NIHSS 
SAE serious adverse event; s/c subcutaneous; NIHSS National Institutes of Health Stroke Scale 
 
